


**INDO US**  
**BIO-TECH LIMITED**

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Date :14.11.2022

To,  
Corporate Relation Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai 400 001

**Sub: Outcome of the Meeting of the Board of Directors of the Company.**  
**Ref. Submission of Unaudited Financial Results for the Quarter and Half year ended on 30<sup>th</sup> September, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**  
**BSE Code: 541304**

Dear Sir,

With regard to the captioned subject and in compliance with the Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company was held on Monday, 14<sup>th</sup> Day of November, 2022 and said Board meeting commenced at 06.00 p.m. and concluded at 07:15 p.m. have inter-alia considered and approved;

1. The Un-audited Standalone financial results, Balance Sheet and Cash Flow Statement along with limited review report of the Company for the quarter and half year ended on 30<sup>th</sup> September, 2022.


These are also being made available on the website of the Company at [www.indousagriseeds.com](http://www.indousagriseeds.com)

Please take the same on your records.

Thanking you,

Yours faithfully,

For, Indo Us Bio Tech Limited


  
Ms. Priyanka Ajudia  
Executive Director




**Regd. Office :**  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061.  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist-Gandhinagar, Gujarat.

**E-mail :** indousexim@gmail.com • **Web :** www.indousagriseeds.com





# INDO US BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



Date: 14/11/2022

To,  
The Deputy Manager,  
The Department of Corporate Services,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Company Code-541304

**SUB: Declaration of Financial Results for the half year ended on 30<sup>th</sup> September, 2022.  
Reference: Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015.**


Dear Sir,

With reference to captioned subject and pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone and Balance Sheet, and Cash Flow Statement for the Quarter and Half year ended on 30<sup>th</sup> September, 2022, along with Limited Review Report for the half year ended on 30<sup>th</sup> September, 2022.

Kindly take the same on your record and oblige us.

Thanking you,

For, Indo Us Bio Tech Limited


  
Ms. Priyanka Ajudia  
Executive Director



**Regd. Office :**  
309, Shanti Mall, Sattadhar Cross Road,  
Opp. Navrang Tower, Ahmedabad-380 061.  
Tele Fax : +91-079-27491807,  
Mobile : +91-9909043999

**DSIR RECOGNITION IN HOUSE R&D UNIT**  
**Factory Address :**  
Village-Bardoli Kanthi,  
Near Indira Nagar, Ta.-Dehgam,  
Dist-Gandhinagar, Gujarat.

**E-mail :** indousexim@gmail.com • **Web :** www.indousagriseeds.com





**LIMITED REVIEW REPORT**

To,  
The Board of Directors  
Indo US Bio-Tech Limited  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited financial results of Indo US Bio-Tech Limited for the half year ended 30<sup>th</sup> September 2022, Assets and Liability Statement and Cash Flow Statement ("The Statement") being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No CIR/CFD/CMD1/44/2019 dated 29<sup>th</sup> March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of Listing Regulations, to the extent applicable.





4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates  
Chartered Accountants  
FRN: 103117W



Gautam Nandawat  
Partner,

M No: 032742

UDIN: 22032742BDBMPU3389



Place: Aurangabad

Date: 14<sup>th</sup> November 2022

**Indo US Bio-Tech Limited**

Disclosure of Standalone Cash Flow Statement as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2022

**Standalone Cash Flow Statement for the Half Year ended on 30th September 2022**

	Amount In	Amount In
	in Lakhs 30-Sep-2022 Unaudited	in Lakhs 31-Mar-2022 Audited
<b>Cash flow from operating activities:</b>		
Net profit before tax as per statement of profit and loss	339.70	548.97
<b>Adjusted for:</b>		
Preliminary expenses	-	1.44
Provision for gratuity	0.72	0.57
Depreciation & amortization	32.75	42.29
Asset written off during the year	-	-
Interest income on loans & advances given	-	(0.26)
Interest & finance costs	50.56	117.58
<b>Operating cash flow before working capital changes</b>	<b>423.73</b>	<b>710.60</b>
<b>Adjusted for:</b>		
(Increase)/ decrease in inventories	264.15	(1,147.75)
(Increase)/ decrease in trade receivables	(1,412.11)	415.30
(Increase)/ decrease in other current assets	2.21	0.81
(Increase)/ decrease in other non current assets	0.50	46.03
Increase/ (decrease) in other non current liabilities	59.45	26.87
Increase/ (decrease) in trade payables	229.00	323.77
Increase/ (decrease) in other current liabilities	2.30	(46.13)
<b>Cash generated from / (used in) operations</b>	<b>(430.76)</b>	<b>329.50</b>
Income taxes paid	(10.50)	(38.68)
<b>Net cash generated from/ (used in) operating activities</b>	<b>[A] (441.26)</b>	<b>290.82</b>
<b>Cash flow from investing activities:</b>		
Purchase of fixed assets and capital advance paid	(50.33)	(396.66)
Subsidy Received against Fixed Assets	12.50	-
Proceeds from sale of shares in Subsidiary Company	0.99	-
Increase/ decrease in short term loans and advances	(117.80)	(143.81)
Interest income on loans & advances given	-	0.26
<b>Net cash flow from/(used) in investing activities</b>	<b>[B] (154.64)</b>	<b>(540.22)</b>
<b>Cash flow from financing activities:</b>		
Proceeds from issue of equity shares / Addition in Capital	836.61	270.86
Dividend Paid	-	(15.17)
Proceeds from long term borrowing (net)	(51.28)	3.70
Proceeds from short term borrowing (net)	(112.97)	99.24
Interest & finance costs	(50.56)	(117.58)
<b>Net cash flow from/(used in) financing activities</b>	<b>[C] 621.80</b>	<b>241.05</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents</b>	<b>[A+B+C] 25.90</b>	<b>(8.35)</b>
Cash & cash equivalents as at beginning of the year	4.83	13.18
<b>Cash &amp; cash equivalents as at end of the year</b>	<b>30.73</b>	<b>4.83</b>

For and on behalf of Board of Directors  
For, INDO US BIO-TECH LIMITED

Jagdish D. Ajudiya  
Managing Director  
DIN: 0174595

Ahmedabad  
14th November 2022



**GAUTAM N ASSOCIATES**  
CHARTERED ACCOUNTANTS

*Gautam*  
(PARTNER)

Indo US Bio-Tech Limited				
Statement of standalone unaudited financial results for the half year ended ended on 30th September 2022				
(Amount in Lakhs)				
PARTICULARS	Half year ended			Year ended
	30-09-2022 (Unaudited)	31-03-2022 (Audited)	30-09-2021 (Unaudited)	31-03-2022 (Audited)
<b>I Income</b>				
Revenue from operations	2,813.24	2,454.66	2,550.65	5,005.31
Other income	0.03	16.18	2.09	18.27
<b>Total income from operations</b>	<b>2,813.27</b>	<b>2,470.85</b>	<b>2,552.74</b>	<b>5,023.59</b>
<b>II Expenses</b>				
Purchases	307.04	115.27	102.44	217.71
Production Expenses	1,498.48	2,061.75	2,458.01	4,519.75
Change in Inventories	268.39	(484.99)	(636.00)	(1,120.99)
Employee benefit expenses	67.04	41.29	29.76	71.04
Finance costs	50.56	56.79	60.79	117.58
Depreciation and amortization expenses	32.75	30.51	13.22	43.73
Other expenses	249.30	371.22	254.57	625.79
<b>Total expenses</b>	<b>2,473.57</b>	<b>2,191.83</b>	<b>2,282.78</b>	<b>4,474.61</b>
<b>III Profit/(Loss) before exceptional items and tax</b>	<b>339.70</b>	<b>279.01</b>	<b>269.96</b>	<b>548.97</b>
<b>IV Exceptional items- Prior Period Items</b>				
<b>V Profit/(Loss) before tax</b>	<b>339.70</b>	<b>279.01</b>	<b>269.96</b>	<b>548.97</b>
<b>VI Tax expenses</b>				
a) Current tax	30.00	25.40	12.50	37.90
b) Income tax prior year	-	2.96	-	2.96
b) Deferred tax	-	(15.62)	-	(15.62)
<b>Total tax expenses</b>	<b>30.00</b>	<b>12.74</b>	<b>12.50</b>	<b>25.24</b>
<b>VII Net Profit/(Loss) for the period/year</b>	<b>309.70</b>	<b>266.27</b>	<b>257.46</b>	<b>523.73</b>
<b>VIII Other comprehensive income (net of tax)</b>				
Items that will not be reclassified to profit or loss:				
i) Remeasurement of post employment benefit obligations	-	-	-	-
ii) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-
<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>IX Total comprehensive income for the period/year (VII+VIII)</b>	<b>309.70</b>	<b>266.27</b>	<b>257.46</b>	<b>523.73</b>
<b>X Paid-up equity share capital (face value of Rs.10 per share)</b>	<b>1,002.60</b>	<b>916.67</b>	<b>606.80</b>	<b>916.67</b>
<b>XI Other equity (excluding revaluation reserve)</b>	<b>4,031.62</b>	<b>2,971.24</b>	<b>1,804.69</b>	<b>2,971.24</b>
<b>XII EPS in Rs. (Face Value of Rs.10/- each)*</b>				
-Basic	3.36	4.34	4.24	8.56
-Diluted	3.36	4.34	4.24	8.56
*not annualised				


Notes

- (1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th November 2022 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) The figures have been regrouped/rearranged wherever necessary.

For and on behalf of Board of Directors  
For, INDO US BIO-TECH LIMITED

Jagdish D Ajudiya  
Managing Director  
DIN: 017459  
Managing Director

Place: Ahmedabad  
Date: 14th November 2022



GAUTAM N ASSOCIATES  
CHARTERED ACCOUNTANTS

(PARTNER)



## Indo US Bio-Tech Limited

Disclosure of Standalone Assets and Liabilities (Balance Sheet) as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September 2022

### Standalone Assets and Liabilities (Balance Sheet) as at 30th September, 2022

	Amount In in Lakhs 30-Sep-22	Amount In in Lakhs 31-Mar-22
	Unaudited	Audited
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' funds</b>		
(a) Share capital	1,002.60	916.67
(b) Reserves and surplus	4,031.62	2,971.24
	<b>5,034.22</b>	<b>3,887.91</b>
<b>Share application money pending allotment</b>		
<b>Non-current liabilities</b>		
(a) Long-term borrowings	288.29	339.57
(b) Deferred tax liability (net)	-	-
(c) Long-term provisions	3.39	3.65
(d) Other Non-current liabilities	164.91	105.46
	<b>456.59</b>	<b>448.67</b>
<b>Current liabilities</b>		
(a) Short-term borrowings	797.64	910.60
(b) Trade payables	-	-
i) total outstanding dues of micro and small enterprises	-	81.98
ii) total outstanding dues of other than micro and small enterprises	483.93	172.95
(c) Other current liabilities	47.56	45.26
(d) Short-term provisions	30.48	10.01
	<b>1,359.61</b>	<b>1,220.80</b>
	<b>6,850.42</b>	<b>5,557.38</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant & Equipments	-	-
Tangible assets	544.12	553.85
Intangible assets	-	-
Capital work-in-progress	247.27	232.46
Intangible assets under development	-	-
(b) Non-current Investments	-	0.99
(c) Deferred tax assets (Net)	41.59	41.59
(d) Long-term loans and advances	25.27	25.27
(e) Other Non-current Assets	22.43	22.93
	<b>880.67</b>	<b>877.09</b>
<b>Current assets</b>		
(a) Current investments	-	-
(b) Inventories	2,071.56	2,335.71
(c) Trade receivables	3,486.24	2,054.13
(d) Cash and cash equivalents	30.73	4.83
(e) Short-term loans and advances	398.73	280.93
(f) Other Current Assets	2.48	4.69
	<b>5,969.74</b>	<b>4,680.29</b>
	<b>6,850.42</b>	<b>5,557.38</b>

Note: Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013.

For and on behalf of Board of Directors

For, INDO US BIO-TECH LIMITED

Jagdish D Ajudiya

Managing Director

DIN: 01745851

Managing Director

Ahemdabad  
14th November 2022



GAUTAM N ASSOCIATES  
CHARTERED ACCOUNTANTS

(PARTNER)